News

BL-1110 may also be developed for the treatment of scleroderma, an autoimmune disease characterized by a hardening and tightening of the skin and connective tissues. The compound, which

The open-label trial (HPV-004) is designed to assess safety, immunogenicity, clinical responses and disease-free survival of INO-3112 in female patients with inoperable invasive cervical cancer. INO-3112 is a

The partnership will focus on combining BIND’s Accurin technology with Roche’s proprietary therapeutic payloads and targeting ligands. BIND Therapeutics chief executive officer Scott Minick said the addition of

Start of the Phase IIa portion of the trial follows the unanimous recommendation of the study’s Data Safety Committee after their review of all Phase Ib safety and

The collaboration between ChromaDex and St. Jude will focus on screening ChromaDex’s natural product libraries against certain biological assays and tumor models with the intent of identifying high

As part of the deal, Celsion’s subsidiary CLSN Laboratories has acquired all assets and assumed certain specified liabilities of EGEN. At the closing, Celsion issued $8.5m worth of

The move will help the company to focus its efforts on a follow-on Phase II randomized, controlled proof-of-concept study, later in 2014. Interim results for the existing AMD

The seventh ANDA filing was in connection with a current development, supply and marketing agreement with Impax Laboratories. The deal designates IGI Laboratories as the developer, manufacturer and

The patent covers methods for treating ulcerative colitis or Crohn’s disease using placenta-derived cells. This patent has already been issued to Pluristem in South Africa and is currently